AdvaMed Names Resmed CEO Mick Farrell as Next Board Chair

AdvaMed, the Medtech Association, announced that Resmed chairman and CEO Michael “Mick” Farrell will be the next chair of the organization’s board of directors.

Farrell will serve a two-year term, starting in January 2026.

“The entire Board and the global industry AdvaMed represents are excited to have Mick as our chair during a rapidly evolving pace of medtech innovation,” said Scott Whitaker, AdvaMed’s president and CEO. “Whether in international forums or in the halls of the U.S. Congress, Mick’s enthusiasm for the power of medtech to change lives is endless and contagious. His egalitarian approach is inspiring. As chairman and CEO of Resmed, he is relentlessly committed to helping people sleep better, breathe better, and live longer, healthier lives. We’ll continue to take inspiration from his vision of life-changing medtech for all.” 

Farrell has been a member of AdvaMed’s board of directors since 2015. He also chairs the International Board Committee and recently joined an AdvaMed CEO delegation to Japan focused on medtech and healthy aging.

He was named CEO of Resmed and joined the company’s board in March 2013, then became chairman of the board in January 2023. Since joining Resmed in 2000, Farrell has served in a variety of senior leadership positions, including president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and earlier positions in marketing and business development.

Before Resmed, he had roles at Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP. Farrell is also a lead independent director at Zimmer Biomet, where he’s a member of the Compensation and Management Development Committee and the Quality, Regulatory and Technology Committee.

“I’m honored by the trust of my peers to serve as chair of AdvaMed,” Farrell said. “It’s a privilege to follow in the footsteps of leaders like Mike Minogue, Ashley McEvoy, and Pete Arduini, who each brought powerful focus to our shared goal of putting patients first, driving innovation, and shaping a better future for healthcare.

He will reveal more details about his priorities in early 2026.

Farrell succeeds Peter Arduini as AdvaMed board chair

Arduini, who is president and CEO of GE HealthCare, was AdvaMed’s interim board chair for several weeks before unanimous election as permanent chair in December 2023.

“Pete’s proven record of leadership over more than three decades in medtech and imaging were critical to AdvaMed at a pivotal period,” Whitaker said. “Under his stewardship, AdvaMed fully integrated its new imaging and digital health tech divisions, securing our position as the only trade association representing the entire medtech and health tech ecosystem, from the companies traditionally considered medtech to tech companies engaging in digital health. 

Achievements in Arduini’s tenure include:

• Firm establishment and integration of AdvaMed’s Imaging and Digital Health Tech divisions, contributing to a membership surge from 398 companies to 615 companies.
• Accreditation of AdvaMed by the American National Standards Institute (ANSI) as a Standards Development Organization (SDO). This ensures AdvaMed may convene stakeholders across the global medical technology ecosystem to create consensus-driven standards for patients, providers, regulators, and innovators worldwide. 
• The strongest momentum to date on the longstanding priority of Medicare coverage of FDA-designated and -authorized breakthrough medtech, with overwhelming passage of legislation from a key congressional committee and support of the concept from top Administration leaders.
• Final Centers for Medicare and Medicaid Services regulations to expand access for millions of Medicare beneficiaries to diagnostic radiopharmaceuticals used to diagnose illnesses including Alzheimer’s, Parkinson’s, heart disease, and certain types of cancer; computed tomography colonography (CTC), a minimally invasive colorectal cancer screening tool; a category of digital mental health treatment devices; and non-opioid treatments for pain relief.
• A final regulation on the ethylene oxide (EtO) used to sterilize half of all medical devices in the United States that was more workable than proposed, preserving the critical sterilization method while continuing to protect public health.
• The largest ever and first international MedTech Conference (Toronto 2024) and the largest MedTech Conference in the United States (San Diego 2025).